Abstract Estrogen mediated signaling affects cell proliferation, differentiation and mammary gland function. The human Estrogen Receptor (hER) is present in 70% of breast cancers. Consequently, estrogen mediated hER signaling plays a critical role in breast cancer diagnosis, prognosis, and treatment.Anti-estrogen, Tamoxifen, targets the LBD and transitions the hER from “agonist” conformation into a structurally unique “antagonist” conformation, which is distinctly recognizable by the position of helix XII. Antiestrogen tamoxifen is a known treatment for hER positive breast cancers. However, due to mutations and hormone-independent activation of/in the hER, breast cancers develop resistance to tamoxifen, and resume growth and malignant progression. Estrogen's action at hER is regulated not only by estrogen, but also by other small molecules and coregulators. A closer look at the compliment of coregulators during acquired tamoxifen resistance shows a significant decrease in the corepressor breast cancer susceptibility (BRCA1) protein expression. BRCA1 directly interacts, from amino acids 67-200, with the hER, from 338-379 and 420-495, LBD/AF2 domain. The interface region of BRCA1 containing the binding motif (amino acids 86-93), which specifically contain two essential chemical features, a hydrophobic core and a charged carboxylic acid is necessary for high affinity binding and hER repression. Here we present several small molecules identified based on these pharmacophoric features as well as ER molecular profiles of conformation sensing peptides. Discovery of conformation sensing protein/peptides would open new avenues for drug development and would lead to advanced clinical studies of hER-conformation sensing small molecules as an entirely new class of anticancer therapy especially in tamoxifen-resistant tumors. Acknowledgements: This research was supported via funds from the New York State, National Institutes of Health (5P20MD002725), through the NCMHD -RIMI program (RVR) and NSF LSAMP Bridge to Doctorate grant (BR). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3901. doi:1538-7445.AM2012-3901
Read full abstract